Literature DB >> 3284526

Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2.

T Waddell1, S Head, M Petric, A Cohen, C Lingwood.   

Abstract

Two Escherichia coli cytotoxins (verotoxins 1 and 2) have been previously implicated in the cytopathology of the Hemolytic Uremic Syndrome. We have examined the glycolipid binding specificity of verotoxin (VT)2. This toxin specifically binds to globotriosyl ceramide (galactose alpha 1-4 galactose beta 1-4 glucosyl ceramide). Removal, or substitution of the terminal a galactose residue with N-acetyl galactosamine in beta 1-3 linkage, deletes binding activity. The toxin does not recognize similar terminal a galactose residues on a glycoglycerolipid. Thus the binding specificity of VT2 is the same as previously reported for VT1. Liposomes containing globotriosyl ceramide are able to specifically remove VT1 and VT2 cytotoxicity and cell lines selected in vitro for resistance to VT1 are cross resistant to VT2.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3284526     DOI: 10.1016/s0006-291x(88)80091-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  74 in total

1.  Relationship of genetic type of Shiga toxin to manifestation of bloody diarrhea due to enterohemorrhagic Escherichia coli serogroup O157 isolates in Osaka City, Japan.

Authors:  Y Nishikawa; Z Zhou; A Hase; J Ogasawara; T Cheasty; K Haruki
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.

Authors:  Abhineet S Sheoran; Igor P Dmitriev; Elena A Kashentseva; Ocean Cohen; Jean Mukherjee; Michelle Debatis; Jonathan Shearer; Jacqueline M Tremblay; Gillian Beamer; David T Curiel; Charles B Shoemaker; Saul Tzipori
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

3.  Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide.

Authors:  T Waddell; A Cohen; C A Lingwood
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

4.  Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood.

Authors:  P C Rowe
Journal:  Can J Infect Dis       Date:  1995-03

5.  A system for production and rapid purification of large amounts of the Shiga toxin/Shiga-like toxin I B subunit.

Authors:  S B Calderwood; D W Acheson; M B Goldberg; S A Boyko; A Donohue-Rolfe
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

6.  Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron.

Authors:  K Ramotar; B Boyd; G Tyrrell; J Gariepy; C Lingwood; J Brunton
Journal:  Biochem J       Date:  1990-12-15       Impact factor: 3.857

7.  Shiga toxin 2 and flagellin from shiga-toxigenic Escherichia coli superinduce interleukin-8 through synergistic effects on host stress-activated protein kinase activation.

Authors:  Dakshina M Jandhyala; Trisha J Rogers; Anne Kane; Adrienne W Paton; James C Paton; Cheleste M Thorpe
Journal:  Infect Immun       Date:  2010-05-03       Impact factor: 3.441

8.  Identification of amino acids critical for the cytotoxicity of Shiga toxin 1 and 2 in Saccharomyces cerevisiae.

Authors:  Rong Di; Eric Kyu; Varsha Shete; Hemalatha Saidasan; Peter C Kahn; Nilgun E Tumer
Journal:  Toxicon       Date:  2010-12-22       Impact factor: 3.033

9.  Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H- in mitomycin-treated mice.

Authors:  J Fujii; T Kita; S Yoshida; T Takeda; H Kobayashi; N Tanaka; K Ohsato; Y Mizuguchi
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

10.  Expression and purification of Shiga-like toxin II B subunits.

Authors:  D W Acheson; S A De Breucker; M Jacewicz; L L Lincicome; A Donohue-Rolfe; A V Kane; G T Keusch
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.